ERG and prostate cancer: ERG was shown to induce the expression of PLA2G7, and knock-down of PLA2G7 significantly reduced the growth of ERG positive, but not ERG negative, prostate cancer cells in vitro, indicating potential as a biomarker and personalized drug target in ERG positive prostate cancers [9].